<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-4SAM9K9X</identifier><date>2017</date><creator>Di Maio, Massimo</creator><creator>Lopes, Gilberto</creator><creator>Pohar Perme, Maja</creator><creator>Rossi, Antonio</creator><creator>Zwitter, Matjaž</creator><relation>documents/doc/4/URN_NBN_SI_doc-4SAM9K9X_001.pdf</relation><relation>documents/doc/4/URN_NBN_SI_doc-4SAM9K9X_001.txt</relation><format format_type="volume">51</format><format format_type="type">article</format><format format_type="issue">iss. 3</format><format format_type="extent">str. 241-251</format><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID_HOST">2780283</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-4SAM9K9X</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">EGFR</subject><subject language_type_id="eng">intercalated treatment</subject><subject language_type_id="slv">lung cancer</subject><subject language_type_id="slv">NSCLC</subject><subject language_type_id="eng">tyrosine -kinase inhibitors</subject><title>Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors</title></Record>